Is infliximab effective for induction of remission in patients with ulcerative colitis?

Inflamm Bowel Dis. 2001 May;7(2):89-93. doi: 10.1097/00054725-200105000-00002.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Crohn Disease / drug therapy*
  • Cyclophosphamide / therapeutic use
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab
  • Models, Animal
  • Monkey Diseases / physiopathology
  • Remission Induction
  • Steroids
  • Thalidomide / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Steroids
  • Tumor Necrosis Factor-alpha
  • CDP 571
  • Thalidomide
  • Cyclophosphamide
  • Infliximab